myriamed – the drug development accelerator

Separating the pharmacological wheat from the chaff is the primary goal of myriamed. Our proprietary human cell and engineered tissue models allow for the simulation of health and disease in the dish. Our platform technologies find broad applications in early stages of drug discovery and refinement of the most promising therapeutic candidates.

Information gained from our advanced engineered tissue models can assist drug developers in defining safe and effective doses for first in human studies. Reduction in attrition rate and acceleration of clinical translation of the most promising therapeutic candidates to address pressing unmet medical needs is what we strive for.

SERVICES

Click below to learn more about the myriamed platform portfolio.

MYR- 6 values

Ownership

We have a strong academic and entrepreneurial background. It is our passion to enable our customers to address unmet medical needs quickly, safely, efficiently, and cost-effectively.

Innovation

We constantly innovate our technology platforms. We respect freedom of ideas and combine both internal and external technology and expertise from around the world to find best solutions.

Communications

We welcome diverse opinions and adverse views presented in a constructive manner. We strive to openly, fairly, and clearly communicate the rationale for our decisions.

Trust

We believe in trusting people internally and externally to quickly deliver solutions to complex system issues. Trust is enhanced by reliability, quality, and honesty.

Success

We value success achieved under high ethical standards and environmental consciousness over success gained at the expense of others. We strive to be responsive to changes in technology and science impacting the needs of our customers.

Financial goal

is healthy and sustainable growth. The long-term prospect of success always lies at the heart of our strategies.

NEWS

by Christian Vitt 0
2021-01-06 15:43
by Christian Vitt
(comments: 0)

We are proud to announce that myriamed is now a member of the Network for Pharma Solutions (NetPhaSol). NetPhaSol is a cooperation network focusing on drug discovery & development.

2021-01-06 15:43
by Christian Vitt
(comments: 0)
by Christian Vitt 0
2020-12-03 16:52
by Christian Vitt
(comments: 0)

Even though vaccines against Covid-19 will be available soon, artificial herd immunity via vaccination will probably not reached until the end of 2021.

2020-12-03 16:52
by Christian Vitt
(comments: 0)
by Christian Vitt 0
2020-11-23 14:02
by Christian Vitt
(comments: 0)

We are proud to announce that myriamed’s myrPlates are now also available in the ZAGENO life science, e-commerce marketplace.

2020-11-23 14:02
by Christian Vitt
(comments: 0)
by Christian Vitt 0
2020-10-30 15:34
by Christian Vitt
(comments: 0)

In STAR Protocols Tibury et al. describe a robust method for the generation of engineered human myocardium (EHM) from pluripotent stem cells (PSCs) in 48 well myriamed myrPlates under defined, serum-free conditions (DOI: 10.1016/j.xpro.2020.100032).

2020-10-30 15:34
by Christian Vitt
(comments: 0)
by Christian Vitt 0
2020-10-26 11:47
by Christian Vitt
(comments: 0)

We proudly announce that myriamed GmbH is now a member of the Ksilink association. The public private association is aiming to render drug development faster and more efficient, heading towards precision medicine.

2020-10-26 11:47
by Christian Vitt
(comments: 0)
by Christian Vitt 0
2020-10-19 14:19
by Christian Vitt
(comments: 0)

myriamed supports the local soccer club SV Puma with a small donation to help them buy new sportswear. We hope that the COVID-19 pandemic will be over soon and team sports can take place again.

2020-10-19 14:19
by Christian Vitt
(comments: 0)

„E Pluribus Unum (out of many - one)“

Separating the pharmacological wheat from the chaff to enhance safety and efficacy of new molecular entities (NMEs) is the primary goal of myriamed. Our unique strengths are high quality secondary screens based on proprietary tissue engineered organ platforms. We offer our support to the pharmaceutical and biotech industry at an early stage of drug development to improve the attrition rate and enhance cost-effectiveness of drug development.

Get in touch with our team!

Dr. Eriona Heta

Research & Development specialist with many years of experience in cardiac tissue engineering, myriamed platforms and genetic engineering. Dr. Heta obtained her PhD in Molecular Medicine at the University Medical Center Göttingen and has extensive knowledge in strategic management.

Get in contact

Dr. Wolf Jockusch

Managing Director

Highly motivated and creative general manager with more than fifteen years of experience in the industrial & academic environment and a strong background in molecular biology and neurophysiology.

Get in contact

Dr. Angelica Roa Lara

Research and Development specialist with more than 10 years of experience in cardiac tissue engineering based on human pluripotent stem cells, and a strong background in molecular biology. Dr. Roa has a PhD in Regenerative Sciences obtained at the Hannover Medical School.

Get in contact

Gunther Zimmermann

Managing Director

Results driven general manager with more than 20 years of experience in personnel and financial matters. In addition to his role at myriamed he is Managing Director at Tissue Systems Holding, procurist at Jobactive and Executive Partner at Hanfried Personaldienstleistungen.

Get in contact

Dr. Uwe Carl

Director Technical Operations

With more than 25 years of experience in the life science environment he has accumulated extensive skills in building up and structuring R&D and production facilities. Before joining myriamed he served for almost 20 years in various roles at IBA Lifesciences.

Get in contact

Copyright 2021 Seaside Media. All Rights Reserved.